KLK3 and prostate cancer: Studies have shown that TH inhibits the activation of the AKT and NF-κB pathways, induces G1/S cell cycle arrest, and inhibits the expression of cyclin D1/E and CDK2/4, ultimately reducing androgen receptor and prostate-specific antigen (PSA) levels, supporting its potential application in prostate cancer treatment [175,176].